国际中药及天然药物的药物警戒对比与思考

doi:10.19803/j.1672-8629.2021.05.02

中国药物警戒 ›› 2021, Vol. 18 ›› Issue (5): 406-410.
DOI: 10.19803/j.1672-8629.2021.05.02

• 中药药物警戒研究与实践专栏 • 上一篇下一篇

国际中药及天然药物的药物警戒对比与思考

吴昊^1,2, 张冰^1,2,*, 林志健^1,2, 张晓朦^1,2

¹北京中医药大学中药学院,北京 102488;
²北京中医药大学中药药物警戒与合理用药研究中心,北京 102488

收稿日期:2020-02-26 出版日期:2021-05-15 发布日期:2021-05-12
通讯作者: ^*张冰,女,博士,教授,主任医师,中药药物警戒与合理用药研究、中药药性理论与名老中医传承研究、中药防治代谢性疾病研究。E-mail:zhangbing6@263.net
作者简介:吴昊,男,在读博士,中药药物警戒与合理用药研究。
基金资助:
国家自然科学基金项目（81874349）;第三批国家高层次人才特殊支持计划（万人计划）教学名师项目;国家中医药领军人才支持计划“岐黄学者”项目;中国毒理学会临床毒理专项课题（CST2020CT501）

Comparison of International Pharmacovigilance of Traditional Chinese Medicine and Natural Medicines

WU Hao^1,2, ZHANG Bing^1,2,*, LIN Zhijian^1,2, ZHANG Xiaomeng^1,2

¹School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 102488, China;
²Center for Pharmacovigilance and Rational Use of Chinese Medicine, Beijing University of Chinese Medicine, Beijing 102488, China

Received:2020-02-26 Online:2021-05-15 Published:2021-05-12

摘要/Abstract

摘要： 目的分析中药及天然药物的药物警戒发展,为中药及天然药物的药物警戒体系建设提供借鉴。方法查阅国内外文献,检索欧美英、大洋洲、亚洲国家和地区的中药及天然药物相关法律法规及指南规范,浏览其药品监管机构官方网站,分析其中药及天然药物的药物警戒监管机构设置、职责和法规内容等。结果中药及天然药物的药物警戒工作在各国家和地区药物警戒系统中均有涉及,欧盟、印度等国家和地区围绕中药及天然药物已建立相关监管机构及颁布了具体的法律法规,但中药及天然药物的药物警戒体系仍需建设。结论中药及天然药物的药物警戒已成为各国家和地区药物警戒体系中的重要组成部分,相较于其他国家和地区我国中药及天然药物的药物警戒体系相对完善,应协同各国家和地区相关药物警戒的发展,推动中药及天然药药物警戒持续研究,为健全全球中药及天然药物的药物警戒体系提供参考。

关键词: 国际, 药物警戒, 欧洲, 美国, 英国, 大洋洲, 亚洲, 中药, 天然药物

Abstract: Objective To provide reference for the construction of pharmacovigilance systems of traditional Chinese medicine(TCM) and natural medicines by analyzing the development of pharmacovigilance of TCM and natural medicines. Methods Domestic and foreign literature was searched. Laws, regulations and guidelines related to TCM and natural medicines in some countries and regions were retrieved, the official websites of drug regulatory agencies were browsed, and pharmacovigilance regulatory agencies, related responsibilities, and regulatory content of TCM and natural medicines in various countries and regions were analyzed. Results Pharmacovigilance of TCM and natural medicines was specified in the pharmacovigilance system in many countries and regions. The European Union, India and other countries had established related regulatory agencies and worked out specific regulatory documents for TCM and natural medicines, but related pharmacovigilance systems were still under construction. Conclusion The pharmacovigilance of TCM and natural medicines has become an important part of pharmacovigilance in various countries and regions. The pharmacovigilance system of TCM and natural medicines in China is relatively complete compared with other countries and regions. China should keep up with the development of pharmacovigilance in various countries to motivate sustained research on pharmacovigilance of TCM and natural medicines and boost the development of global pharmacovigilance systems of TCM and natural medicines.

Key words: international, pharmacovigilance, European, American, natural medicines, United Kingdom, Oceania, Asian, traditional Chinese medicine (TCM)

中图分类号:

R28R944.1

吴昊, 张冰, 林志健, 张晓朦. 国际中药及天然药物的药物警戒对比与思考[J]. 中国药物警戒, 2021, 18(5): 406-410.

WU Hao, ZHANG Bing, LIN Zhijian, ZHANG Xiaomeng. Comparison of International Pharmacovigilance of Traditional Chinese Medicine and Natural Medicines[J]. Chinese Journal of Pharmacovigilance, 2021, 18(5): 406-410.

参考文献

[1] MHRA.Illegal herbal remedies containing aristolochia:vigilance needed[EB/OL].(2014-12-11)[2021-02-20].https://www.gov.uk/drug-safety-update-illegal-herbal-remedies-containing-aristolochia-vigilance-needed.
[2] TGA.Australian Adverse Drug Reactions Bulletin,Vol 18,No 1[EB/OL].(1999-02)[2021-02-20].https://www.tga.gov.au/publication-issue/australian-adverse-drug-reactions-bulletin-vol-18-no-1.
[3] EMA.Committee on Herbal Medicinal Products (HMPC)[EB/OL].(2004-09)[2021-02-20].https://www.ema.europa.eu/en/committees/committee-herbal-medicinal-products-hmpc.
[4] EMA.Medicines[EB/OL].[2021-02-20].https://www.ema.europa.eu/en/medicines/field_ema_web_categories%253Aname_field/Herbal.
[5] EMA.Good Pharmacovigilance Practices[EB/OL].(2012-07-26)[2021-02-20].https://www.ema.europa.eu/en/search/search?search_api_views_fulltext=GVP.
[6] EMA.European medicines agency finalises first set of guidelines on good pharmacovigilance practices[EB/OL].(2012-06-25)[2021-02-20].https://www.ema.europa.eu/en/news/european-medicines-agency-finalises-first-set-guidelines-good-pharmacovigilance-practices.
[7] Zhou F.Research on the British traditional herbal medicine management legal system and the British registration strategy of Chinese medicines[J].Global Traditional Chinese Medicine(环球中医药),2014,7(11):851-855.
[8] MHRA.Herbal medicines regulation:Licensed herbal medicines[EB/OL].[2021-2-20].http://www.mhra.gov.uk/Howweregulate/Medicines/Herbalmedicinesregulation/Licensedherbal-medicines/index.htm.
[9] MHRA.Banned and restricted herbal ingredients[EB/OL].(2014-12-18)[2021-2-20].https://www.gov.uk/government/publications/list-of-banned-or-restricted-herbal-ingredients-for-medicinal-use-banned-and-restricted-herbal-ingredients.
[10] FDA.Dietary Supplement Products &Ingredients[EB/OL].(2020-10-13)[2021-2-20].https://www.fda.gov/food/dietary-supplements/dietary-supplement-products-ingredients.
[11] FDA.Drug safety oversight board[EB/OL].[2021-02-20].https://www.fda.gov/about-fda-center-drug-evaluation-and-research-cder-drug-safety-oversight-board.
[12] FDA.Recalls,market withdrawals,&safety alerts[EB/OL].[2021-02-20].https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts.
[13] FDA.Alerts,advisories &safety information[EB/OL].(2001-04)[2021-02-20].https://www.fda.gov/food/recalls-outbreaks-emergencies-alerts-advisories-safety-information.
[14] FDA.Pharmacy compounding advisory committee meeting 3-16[EB/OL].(2016-03)[2021-02-20].https://search.usa.gov/search?query=Anthraquinone&affiliate=fda1.
[15] FDA.Current good manufacturing practice (CGMP) regulations[EB/OL].(2020-09-21)[2021-02-20].https://www.fda.gov/drugs/pharmaceutical-quality-resources-current-good-manufacturing-practice-cgmp-regulations.
[16] TGA.Complementary medicines[EB/OL].(2020-05-20)[2021-02-20].https://www.tga.gov.au/complementary-medicines.
[17] TGA.Complementary and OTC medicines regulatory and technical consultative forum (ComTech)[EB/OL].(2021-01-08)[2021-02-20].https://www.tga.gov.au/committee/complementary-and-otc-medicines-regulatory-and-technical-consultative-forum-comtech.
[18] Wang H,Zhu Y.Application status of classical prescription in traditional Chinese medicine and Japanese Kampo medicine[J].Chinese Traditional and Herbal Drugs(中草药),2019,50(15):3714-3719.
[19] Xiao YY,Yang ZB.Enlightenment from the development of kampo medicine in japan[J].Chinese Journal of Dermatovenerology of Integrated Traditional and Western Medicine.(中国中西医结合皮肤性病学杂志),2018,17(6):554-558.
[20] Information system on safety and effectiveness for health foods.Designated ingredients,etc[EB/OL].(2020-06-01)[2021-02-20].https://hfnet.nibiohn.go.jp-contents-detail4291.html.
[21] Ministry of Health and Family Welfare.Departments of Health and Family Welfare[EB/OL].[2021-02-20].https://main.mohfw.gov.in/organisation/Departments-of-Health-and-Family-Welfare.
[22] Lin ZJ,Zhang XM,Zhang B,et al.General introduction and practice of pharmacovigilance system of Indian traditional medicine[J].Practical Pharmacy and Clinical Remedies(实用药物与临床),2018,21(3):354-358.
[23] HSA.Regulatory overview of traditional medicines[EB/OL].(2020-09-10)[2021-02-20].https://www.hsa.gov.sg/traditional-medicines-regulatory-overview-of-traditional-medicines.
[24] HSA.Traditional medicinal materials:understand the requirements for the import and sale of traditional medicinal materials in Singapore[EB/OL].(2019-10-10)[2021-02-20].https://www.hsa.gov.sg/traditional-medicines/traditional-medicinal-materials.
[25] HSA.Report adverse events[EB/OL].[2021-02-20].https://www.hsa.gov.sg/traditional-medicines/report-adverse-events.
[26] MOH.Medicines Act[EB/OL].(1987-03-30)[2021-02-20].https://sso.agc.gov.sg/Act-MA1975#pr8-.
[27] MFDS.Pharmaceutical Affairs Act[EB/OL].(2016-05-29)[2021-02-20].https://www.mfds.go.kr/eng/brd/m_18-view.do?seq=71344&srchFr=&srchTo=&srchWord=&srchTp=&itm_seq_1=0&itm_seq_2=0&multi_itm_seq=0&company_cd=&company_nm=&page=3.
[28] Ministry of Food and Drug Safety[EB/OL].[2021-2-20].https://www.mfds.go.kr/eng/wpge/m_47-de011033l001.do.
[29] MFDS.National institute of food and drug safety evaluation[EB/OL][2021-02-20].https://www.mfds.go.kr/eng/wpge-m_48/de011033l002.do.
[30] MFDS.Herbal medicine management team,herbal medicine evaluation team[EB/OL][2021-02-20].https://www.mfds.go.kr/eng/wpge/m_43/de011030l001.do.

国际中药及天然药物的药物警戒对比与思考

Comparison of International Pharmacovigilance of Traditional Chinese Medicine and Natural Medicines

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	李嘉昕, 刘慧敏, 钱文秀, 马宁, 宋丽丽, 李遇伯. 基于中药系统毒理学数据库的中药致肾毒性及药物规律研究[J]. 中国药物警戒, 2024, 21(2): 173-180.
[2]	张建, 方慧华. 某院活血化瘀类中药注射剂使用评价标准建立的探索[J]. 中国药物警戒, 2024, 21(2): 185-189.
[3]	柏兆方, 湛小燕, 姚清, 陈思敏, 赵旭, 肖小河. 中药安全性评价理论创新与技术突破：病证毒理学[J]. 中国药物警戒, 2024, 21(1): 6-14.
[4]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[5]	方志娥, 李承贤, 柏兆方, 赵旭, 王伽伯, 肖小河. 马兜铃酸致肝癌的客观性研究与思考[J]. 中国药物警戒, 2024, 21(1): 20-24.
[6]	高源, 石伟, 肖小河, 柏兆方, 王伽伯. 特异质型药物性肝损伤体内评价模型研究进展[J]. 中国药物警戒, 2024, 21(1): 33-39.
[7]	李舒冉, 郭姗姗, 冀祖恩, 张薇, 崔晓兰. 新型冠状病毒感染后认知功能障碍的研究现状[J]. 中国药物警戒, 2024, 21(1): 59-64.
[8]	刘敏, 陈艳, 刘文东, 王海学. 药物临床试验期间安全性数据快速报告的更新与思考[J]. 中国药物警戒, 2024, 21(1): 98-101.
[9]	夏旭东, 黎美霞, 孙阳, 杨胜亚. 药品上市许可持有人药物警戒远程检查流程探讨[J]. 中国药物警戒, 2023, 20(9): 967-970.
[10]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[11]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[12]	沈艳杰, 吴奕卿. 临床试验期间不良事件管理的实践与思考[J]. 中国药物警戒, 2023, 20(9): 982-986.
[13]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.
[14]	黄锦坚, 张晓朦, 张冰, 丁雪丽, 杨莹, 林志健. 降尿酸药物的心血管风险信号挖掘及机制研究[J]. 中国药物警戒, 2023, 20(8): 866-871.
[15]	梅雨, 朱越, 张慧婷, 肖成荣, 高月, 马增春. 基于网络药理学和实验验证探讨中药复方CB001对低剂量辐射防护的作用机制[J]. 中国药物警戒, 2023, 20(8): 872-879.